In order to obtain a "high priority" subset of targets in the gut where to focus experimentation first, we searched for the anatomically defined group of ailments called "intestinal diseases", considering that, while gut metabolites can cross the gut wall and are known to interact with proteins located in other organs, the vast majority of interactions of these metabolites are expected to occur with intestinal targets. In turn, the subset of proteins known to be associated with intestinal diseases is expected to be involved in signaling pathways and interactions in the gut and therefore to be of high biological relevance. In this way, a total of 454 of the metabolite-interacting targets (~43% of the total human proteins) are associated to at least one of these diseases. Interestingly, gut metabolites display a highly significant trend to interact with targets associated with intestinal diseases (p-value = 2e-33 in Fisher exact test, by considering 20412 total proteins and 5587 intestinal disease associated proteins). Also, 57 of the 191 intestinal diseases are associated to a gut-metabolite interacting protein.